

PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/590,445 – Conf. # 6734
				Filing Date	August 24, 2006
				First Named Inventor	Michael Jung
				Art Unit	1614
				Examiner Name	James D. Anderson
Sheet	3	of	7	Attorney Docket Number	58086-235854

	C10	Keown et al., <i>Methods in Enzymology</i> , 185:527-537 (1990).	
	C11	Mansour et al., <i>Nature</i> , 330:340-352 (1990).	
	C12	Muller et al., 1991, <i>Mol. & Cell. Bio.</i> 11:1763.	
	C13	Uhaub et al., <i>Proc. Natl. Acad. Sci. USA</i> , 77:4216 (1980).	
	C14	Stinebaugh et al., <i>Nature</i> , 282:30 (1979).	
	C15	Kingsman et al., <i>Gene</i> , 7: 141 (1979).	
	C16	Tschumper et al., <i>Gene</i> , 10: 137 (1980).	
	<u>ISR/</u> C17	Jones, <i>Genetics</i> , 85:23 (1977).	
	C18	Feldman, B.J. & Feldman, D. The development of androgen-independent prostate cancer. <i>Nat Rev Cancer</i> 1, 34-45 (2001).	
	C19	Gelman, E.P. Molecular biology of the androgen receptor. <i>J Clin Oncol</i> 20, 3004-15 (2002).	
	C20	Balk, S.P. Androgen receptor as a target in androgen-independent prostate cancer. <i>Urology</i> 60, 132-8; discussion 138-9 (2002).	
	C21	Taplin, M.E. et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. <i>Cancer Res</i> 59, 2511-5 (1999).	
	C22	Taplin, M.E. et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. <i>J Clin Oncol</i> 21, 2673-8 (2003).	
	C23	Vieckes, T. et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. <i>Nat Genet</i> 9, 401-6 (1995).	
	C24	Taplin, M.E. et al. Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer. <i>N Engl J Med</i> 332, 1393-8 (1995).	
	C25	Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. <i>Biochem Biophys Res Commun</i> 173, 534-40 (1990).	
	C26	Matias, P.M. et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. <i>J Med Chem</i> 45, 1439-46 (2002).	
	C27	Craft, N., Shostak, Y., Carey, M. & Sawyers, C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. <i>Nat Med</i> 5, 280-5 (1999).	
	C28	Ciccioli, D. et al. Androgen receptor phosphorylation: Regulation and identification of the phosphorylation sites. <i>J Biol Chem</i> 277, 29304-14 (2002).	
	C29	Kato, S. et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. <i>Science</i> 270, 1491-4 (1995).	
	C30	Font de Mora, J. & Brown, M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. <i>Mol Cell Biol</i> 20, 5041-7 (2000).	
	C31	Trombley, A., Trombley, G.B., Labrie, F. & Ciguero, V. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. <i>Mol Cell</i> 3, 513-9 (1999).	

Examiner Signature	/Savitha Rao/	Date Considered	03/23/2010
--------------------	---------------	-----------------	------------